aspirin has been researched along with Renal Insufficiency in 41 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Renal Insufficiency: Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Whether aspirin may reduce the risk for CVD, death, and kidney failure outcomes is uncertain." | 9.22 | Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. ( Bostom, A; Carpenter, M; Dad, T; Hunsicker, L; Joseph, A; Kusek, JW; Levey, AS; Pfeffer, M; Tighiouart, H; Weiner, DE, 2016) |
| "In a laboratory substudy of the PRAGUE-8 trial, the influences of nonmodifiable (age and sex) and modifiable (body mass index and tobacco smoke) factors, comorbidity (hypertension, hyperlipidemia, diabetes mellitus, and renal insufficiency) and cotherapy (statin, aspirin, and heparin), on the course of clopidogrel efficacy were investigated in 105 patients pretreated with clopidogrel >or=6 hours before coronary angiography +/- percutaneous coronary intervention." | 9.14 | Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox". ( Bilkova, D; Kala, P; Marinov, I; Motovska, Z; Petr, R; Simek, S; Widimsky, P, 2009) |
| "This study is the largest to investigate platelet aggregation in stable coronary artery disease patients receiving aspirin as single antithrombotic therapy." | 7.85 | Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S; Würtz, M, 2017) |
| "Adjusted survival curves showed that the usage of aspirin was not associated with ischemic stroke, hospitalization for bleeding events, cardiovascular mortality or all-cause mortality, however, it was significantly associated with renal failure." | 7.85 | Different impact of aspirin on renal progression in patients with predialysis advanced chronic kidney disease with or without previous stroke. ( Chang, HR; Hsiao, KC; Huang, JY; Hung, TW; Lee, CT; Liaw, YP, 2017) |
| " Whether aspirin may reduce the risk for CVD, death, and kidney failure outcomes is uncertain." | 5.22 | Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. ( Bostom, A; Carpenter, M; Dad, T; Hunsicker, L; Joseph, A; Kusek, JW; Levey, AS; Pfeffer, M; Tighiouart, H; Weiner, DE, 2016) |
| "In a laboratory substudy of the PRAGUE-8 trial, the influences of nonmodifiable (age and sex) and modifiable (body mass index and tobacco smoke) factors, comorbidity (hypertension, hyperlipidemia, diabetes mellitus, and renal insufficiency) and cotherapy (statin, aspirin, and heparin), on the course of clopidogrel efficacy were investigated in 105 patients pretreated with clopidogrel >or=6 hours before coronary angiography +/- percutaneous coronary intervention." | 5.14 | Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox". ( Bilkova, D; Kala, P; Marinov, I; Motovska, Z; Petr, R; Simek, S; Widimsky, P, 2009) |
| "The results of the VIGOR study that demonstrated an increase in risk of myocardial infarction with rofecoxib, can probably be explained by an anti-thrombotic effect of naproxene, the high dose of rofecoxib used, the type of patients included or the fact that aspirin had been contraindicated." | 4.82 | [Renal and cardiovascular effects of non-steroidal anti-inflammatories and selective cox 2 inhibitors]. ( Deray, G, 2004) |
| "This study is the largest to investigate platelet aggregation in stable coronary artery disease patients receiving aspirin as single antithrombotic therapy." | 3.85 | Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S; Würtz, M, 2017) |
| "Adjusted survival curves showed that the usage of aspirin was not associated with ischemic stroke, hospitalization for bleeding events, cardiovascular mortality or all-cause mortality, however, it was significantly associated with renal failure." | 3.85 | Different impact of aspirin on renal progression in patients with predialysis advanced chronic kidney disease with or without previous stroke. ( Chang, HR; Hsiao, KC; Huang, JY; Hung, TW; Lee, CT; Liaw, YP, 2017) |
| "Dual-antiplatelet therapy with aspirin and clopidogrel after percutaneous coronary intervention reduces the risk for coronary thrombotic events (CTEs) at the expense of increasing risk for major bleeding (MB)." | 3.83 | Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. ( Ariti, C; Baber, U; Chieffo, A; Cohen, DJ; Colombo, A; Dangas, G; Gibson, CM; Giustino, G; Henry, TD; Kini, AS; Kirtane, AJ; Krucoff, MW; Litherland, C; Mehran, R; Moliterno, DJ; Pocock, S; Sartori, S; Steg, PG; Stone, GW; Weisz, G; Witzenbichler, B, 2016) |
| "2% of dabigatran-treated patients had renal insufficiency requiring a dose reduction." | 3.83 | Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy. ( Barra, ME; Connors, JM; Fanikos, J; Goldhaber, SZ; Piazza, G; Sylvester, KW, 2016) |
| "Platelet function analyses, which included measures of platelet aggregation and activation, were performed in 173 T2DM patients with coronary artery disease on chronic treatment with aspirin and clopidogrel." | 3.74 | Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. ( Alfonso, F; Angiolillo, DJ; Bañuelos, C; Bass, TA; Bernardo, E; Costa, MA; Escaned, J; Fernandez-Ortiz, A; Guzman, LA; Hernández-Antolin, R; Jimenez-Quevedo, P; Macaya, C; Moreno, R; Palazuelos, J; Sabaté, M, 2007) |
| "In patients with RI undergoing PCI, adding abciximab to clopidogrel plus aspirin increases the risk of bleeding without benefit in reducing the risk of ischemic complications within the first 30 days." | 3.74 | Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function. ( Kastrati, A; Mann, JF; Mehilli, J; Ndrepepa, G; Pinkau, T; Schömig, A; Schulz, S, 2008) |
| "Compared with patients with no renal insufficiency, patients with moderate renal insufficiency were less likely to receive aspirin, beta-blockers, thrombolytic therapy, angiography, and angioplasty during hospitalization." | 3.71 | Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. ( Browner, WS; Chertow, GM; Heidenreich, PA; McClellan, MB; Noguchi, H; Shlipak, MG, 2002) |
| "Age and left bundle branch block were strong negative predictors for early reperfusion therapy in patients with prior antithrombotic treatment." | 1.35 | Impact of chronic antithrombotic therapy on hospital course of patients with acute myocardial infarction. ( Bauer, T; Bestehorn, K; Gitt, A; Jünger, C; Koeth, O; Senges, J; Towae, F; Zahn, R; Zeymer, U, 2009) |
| " We assessed the cumulative incidence of major adverse cardiac events (death, acute myocardial infarction, and target-vessel revascularization) and angiographic stent thrombosis during 2-year follow-up." | 1.34 | Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. ( Aurier, E; Benassi, A; Cremonesi, A; Grilli, R; Guastaroba, P; Magnavacchi, P; Manari, A; Maresta, A; Marzocchi, A; Percoco, G; Piovaccari, G; Saia, F; Varani, E, 2007) |
| "Patients with renal failure received adjunctive and reperfusion therapies less frequently than those with normal renal function (P < 0." | 1.31 | Acute myocardial infarction and renal dysfunction: a high-risk combination. ( Albright, RC; Dvorak, DL; Herzog, CA; Jaffe, AS; Kopecky, SL; Miller, WL; Murphy, JG; Reeder, GS; Williams, BA; Wright, RS, 2002) |
| "Pulmonary edema was rare and acute renal failure did not develop in any women." | 1.30 | Safety of labor epidural anesthesia for women with severe hypertensive disease. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. ( Caritis, SN; Dombrowski, MP; Hauth, JC; Hogg, B; Klebanoff, M; Landon, M; Lindheimer, M; MacPherson, C; McNellis, D; Meis, PJ; Miodovnik, M; Paul, R; Roberts, JM; Sibai, BM; Thurnau, GR; Van Dorsten, JP, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (9.76) | 18.7374 |
| 1990's | 2 (4.88) | 18.2507 |
| 2000's | 22 (53.66) | 29.6817 |
| 2010's | 11 (26.83) | 24.3611 |
| 2020's | 2 (4.88) | 2.80 |
| Authors | Studies |
|---|---|
| Gajanana, D | 1 |
| Rogers, T | 1 |
| Weintraub, WS | 1 |
| Kolm, P | 1 |
| Iantorno, M | 1 |
| Khalid, N | 1 |
| Chen, Y | 1 |
| Shlofmitz, E | 1 |
| Khan, JM | 1 |
| Musallam, A | 1 |
| Ben-Dor, I | 1 |
| Satler, LF | 1 |
| Zhang, C | 1 |
| Torguson, R | 1 |
| Waksman, R | 1 |
| Kaplovitch, E | 1 |
| Eikelboom, JW | 1 |
| Dyal, L | 1 |
| Aboyans, V | 1 |
| Abola, MT | 1 |
| Verhamme, P | 1 |
| Avezum, A | 1 |
| Fox, KAA | 1 |
| Berkowitz, SD | 1 |
| Bangdiwala, SI | 1 |
| Yusuf, S | 1 |
| Anand, SS | 1 |
| Larsen, SB | 1 |
| Grove, EL | 1 |
| Neergaard-Petersen, S | 1 |
| Würtz, M | 1 |
| Hvas, AM | 1 |
| Kristensen, SD | 1 |
| Attia, JR | 1 |
| Pearce, R | 1 |
| Stompór, T | 1 |
| Undas, A | 1 |
| Sennesael, AL | 1 |
| Dogné, JM | 1 |
| Spinewine, A | 1 |
| Dad, T | 1 |
| Tighiouart, H | 1 |
| Joseph, A | 1 |
| Bostom, A | 1 |
| Carpenter, M | 1 |
| Hunsicker, L | 1 |
| Kusek, JW | 1 |
| Pfeffer, M | 1 |
| Levey, AS | 1 |
| Weiner, DE | 1 |
| Baber, U | 1 |
| Mehran, R | 1 |
| Giustino, G | 1 |
| Cohen, DJ | 1 |
| Henry, TD | 1 |
| Sartori, S | 1 |
| Ariti, C | 1 |
| Litherland, C | 1 |
| Dangas, G | 1 |
| Gibson, CM | 1 |
| Krucoff, MW | 1 |
| Moliterno, DJ | 1 |
| Kirtane, AJ | 1 |
| Stone, GW | 1 |
| Colombo, A | 1 |
| Chieffo, A | 1 |
| Kini, AS | 1 |
| Witzenbichler, B | 1 |
| Weisz, G | 1 |
| Steg, PG | 1 |
| Pocock, S | 1 |
| Barra, ME | 1 |
| Fanikos, J | 1 |
| Connors, JM | 1 |
| Sylvester, KW | 1 |
| Piazza, G | 1 |
| Goldhaber, SZ | 1 |
| Hsiao, KC | 1 |
| Huang, JY | 1 |
| Lee, CT | 1 |
| Hung, TW | 1 |
| Liaw, YP | 1 |
| Chang, HR | 1 |
| Scharf, RE | 1 |
| Motovska, Z | 1 |
| Widimsky, P | 1 |
| Petr, R | 1 |
| Bilkova, D | 1 |
| Marinov, I | 1 |
| Simek, S | 1 |
| Kala, P | 1 |
| Herbers, AH | 1 |
| Verbruggen, B | 1 |
| Van de Veerdonk, F | 1 |
| Van Kraaij, M | 1 |
| Blijlevens, NM | 1 |
| Novakova, IR | 1 |
| Bauer, T | 1 |
| Gitt, A | 1 |
| Zahn, R | 1 |
| Jünger, C | 1 |
| Koeth, O | 1 |
| Towae, F | 1 |
| Bestehorn, K | 1 |
| Senges, J | 1 |
| Zeymer, U | 1 |
| Ponikowski, P | 1 |
| Ronco, C | 1 |
| Anker, SD | 1 |
| Labos, C | 1 |
| Dasgupta, K | 1 |
| Nedjar, H | 1 |
| Turecki, G | 1 |
| Rahme, E | 1 |
| Lip, GY | 1 |
| Shlipak, MG | 1 |
| Heidenreich, PA | 1 |
| Noguchi, H | 1 |
| Chertow, GM | 1 |
| Browner, WS | 1 |
| McClellan, MB | 1 |
| Wright, RS | 1 |
| Reeder, GS | 1 |
| Herzog, CA | 1 |
| Albright, RC | 1 |
| Williams, BA | 1 |
| Dvorak, DL | 1 |
| Miller, WL | 1 |
| Murphy, JG | 1 |
| Kopecky, SL | 1 |
| Jaffe, AS | 1 |
| Comarow, A | 1 |
| Collet, JP | 1 |
| Montalescot, G | 1 |
| Fine, E | 1 |
| Golmard, JL | 1 |
| Dalby, M | 1 |
| Choussat, R | 1 |
| Ankri, A | 1 |
| Dumaine, R | 1 |
| Lesty, C | 1 |
| Vignolles, N | 1 |
| Thomas, D | 1 |
| SMITH, WW | 1 |
| BERGEN, W | 1 |
| CONDON, JF | 1 |
| FENNELLY, JJ | 1 |
| LASKER, N | 1 |
| BEVERIDGE, GW | 1 |
| FORSHALL, W | 1 |
| MUNRO, JF | 1 |
| OWEN, JA | 1 |
| WESTON, IA | 1 |
| YOUNG, JV | 1 |
| HAYDON, GB | 1 |
| GRAY, CP | 1 |
| HECKER, SP | 1 |
| LEE, PR | 1 |
| Gerrah, R | 2 |
| Izhar, U | 1 |
| Deray, G | 1 |
| Humke, U | 1 |
| Takahashi, M | 1 |
| Siemer, S | 1 |
| Uder, M | 1 |
| Ehrlich, S | 1 |
| Tshori, S | 1 |
| Sahar, G | 1 |
| Ozdal, OL | 1 |
| Ozden, C | 1 |
| Benli, K | 1 |
| Gökkaya, S | 1 |
| Bulut, S | 1 |
| Memiş, A | 1 |
| Abbott, KC | 1 |
| Bohen, EM | 1 |
| Yuan, CM | 1 |
| Yeo, FE | 1 |
| Sawyers, ES | 1 |
| Perkins, RM | 1 |
| Lentine, KL | 1 |
| Oliver, DK | 1 |
| Galey, J | 1 |
| Sebastianelli, ME | 1 |
| Scally, JP | 1 |
| Taylor, AJ | 1 |
| Boal, TR | 1 |
| Marzocchi, A | 1 |
| Saia, F | 1 |
| Piovaccari, G | 1 |
| Manari, A | 1 |
| Aurier, E | 1 |
| Benassi, A | 1 |
| Cremonesi, A | 1 |
| Percoco, G | 1 |
| Varani, E | 1 |
| Magnavacchi, P | 1 |
| Guastaroba, P | 1 |
| Grilli, R | 1 |
| Maresta, A | 1 |
| Angiolillo, DJ | 1 |
| Bernardo, E | 1 |
| Sabaté, M | 1 |
| Jimenez-Quevedo, P | 1 |
| Costa, MA | 1 |
| Palazuelos, J | 1 |
| Hernández-Antolin, R | 1 |
| Moreno, R | 1 |
| Escaned, J | 1 |
| Alfonso, F | 1 |
| Bañuelos, C | 1 |
| Guzman, LA | 1 |
| Bass, TA | 1 |
| Macaya, C | 1 |
| Fernandez-Ortiz, A | 1 |
| Pinkau, T | 1 |
| Ndrepepa, G | 1 |
| Kastrati, A | 1 |
| Mann, JF | 1 |
| Schulz, S | 1 |
| Mehilli, J | 1 |
| Schömig, A | 1 |
| John, WG | 1 |
| Hogg, B | 1 |
| Hauth, JC | 1 |
| Caritis, SN | 1 |
| Sibai, BM | 1 |
| Lindheimer, M | 1 |
| Van Dorsten, JP | 1 |
| Klebanoff, M | 1 |
| MacPherson, C | 1 |
| Landon, M | 1 |
| Paul, R | 1 |
| Miodovnik, M | 1 |
| Meis, PJ | 1 |
| Thurnau, GR | 1 |
| Dombrowski, MP | 1 |
| McNellis, D | 1 |
| Roberts, JM | 1 |
| Rexrode, KM | 1 |
| Buring, JE | 1 |
| Glynn, RJ | 1 |
| Stampfer, MJ | 1 |
| Youngman, LD | 1 |
| Gaziano, JM | 1 |
| Aviles, RJ | 1 |
| Askari, AT | 1 |
| Lindahl, B | 1 |
| Wallentin, L | 1 |
| Jia, G | 1 |
| Ohman, EM | 1 |
| Mahaffey, KW | 1 |
| Newby, LK | 1 |
| Califf, RM | 1 |
| Simoons, ML | 1 |
| Topol, EJ | 1 |
| Berger, P | 1 |
| Lauer, MS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424] | Phase 3 | 27,395 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients: An Observational Single-Arm Study (The PARIS Registry)[NCT00998127] | 5,031 participants (Actual) | Observational | 2009-06-30 | Completed | |||
| BIcarbonato di Sodio e N-Acetilcisteina Nella Prevenzione Della Nefropatia da Mezzo di Contrasto Nell'infaRto mIocardico acutO(Registro BINARIO)[NCT01218178] | 520 participants (Actual) | Observational | 2008-06-30 | Completed | |||
| The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093] | 280 participants (Actual) | Observational | 2014-06-30 | Completed | |||
| A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330] | Phase 4 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| [NCT00000500] | Phase 3 | 0 participants | Interventional | 1981-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 313 |
| Rivaroxaban 5mg + Aspirin Placebo | 366 |
| Rivaroxaban Placebo + Aspirin 100mg | 378 |
Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 282 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 389 |
| Rivaroxaban 5mg + Aspirin Placebo | 453 |
| Rivaroxaban Placebo + Aspirin 100mg | 516 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 329 |
| Rivaroxaban 5mg + Aspirin Placebo | 397 |
| Rivaroxaban Placebo + Aspirin 100mg | 450 |
Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 379 |
| Rivaroxaban 5mg + Aspirin Placebo | 448 |
| Rivaroxaban Placebo + Aspirin 100mg | 496 |
Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 353 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 288 |
| Rivaroxaban 5mg + Aspirin Placebo | 255 |
| Rivaroxaban Placebo + Aspirin 100mg | 170 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 138 |
5 reviews available for aspirin and Renal Insufficiency
| Article | Year |
|---|---|
[Acquired platelet function disorders: pathogenesis, classification, frequency, diagnosis, clinical management].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelet Disorders; Blood Platelets; Coronar | 2008 |
Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biomarkers; Echocardiography; Female; Fibrinolyt | 2013 |
[Renal and cardiovascular effects of non-steroidal anti-inflammatories and selective cox 2 inhibitors].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Dose-Response Relations | 2004 |
[Metabolic acidosis].
Topics: Acid-Base Equilibrium; Acidosis; Aspirin; Bicarbonates; Humans; Hydrogen-Ion Concentration; Hypoxia; | 2006 |
Glycated haemoglobin analysis.
Topics: Aspirin; Blood Glucose; Chemistry, Clinical; Chromatography, Affinity; Chromatography, High Pressure | 1997 |
5 trials available for aspirin and Renal Insufficiency
| Article | Year |
|---|---|
Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Double | 2021 |
Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cohort Studi | 2016 |
Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox".
Topics: Age Factors; Aged; Angioplasty, Balloon, Coronary; Aspirin; Body Mass Index; Cell Adhesion Molecules | 2009 |
Beneficial effect of aspirin on renal function in patients with renal insufficiency postcardiac surgery.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiopulmonary Bypass; Coronary Arte | 2004 |
Effect of short-term finasteride therapy on peroperative bleeding in patients who were candidates for transurethral resection of the prostate (TUR-P): a randomized controlled study.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Finasteride; Hemoglobins; Humans; Male; Middle Aged; Pro | 2005 |
31 other studies available for aspirin and Renal Insufficiency
| Article | Year |
|---|---|
Ischemic Versus Bleeding Outcomes After Percutaneous Coronary Interventions in Patients With High Bleeding Risk.
Topics: Aged; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Artery Disease; Dual Anti-Platelet | 2020 |
Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease.
Topics: Aged; Aspirin; Brain Ischemia; Coronary Artery Disease; Coronary Thrombosis; Drug Resistance; Female | 2017 |
The use, misuse and abuse of dabigatran.
Topics: Advertising; Anticoagulants; Antithrombins; Aspirin; Australia; Benzimidazoles; beta-Alanine; Cardio | 2013 |
High rate of aspirin resistance in advanced kidney failure: does it matter?
Topics: Aspirin; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Renal Insufficiency | 2014 |
Optimizing the Safe Use of Direct Oral Anticoagulants in Older Patients: A Teachable Moment.
Topics: Acenocoumarol; Administration, Oral; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation | 2015 |
Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Anemia; Aspirin; Body Mass Index; Clopidogrel; Cohort St | 2016 |
Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy.
Topics: Aged; Aged, 80 and over; Antithrombins; Aspirin; Atrial Fibrillation; Comorbidity; Creatinine; Dabig | 2016 |
Different impact of aspirin on renal progression in patients with predialysis advanced chronic kidney disease with or without previous stroke.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cause of Death; Comorbidity; Female; Hematinics; Hemorrhage; | 2017 |
Misleading one-stage coagulation factor assay during rFVIIa treatment in lupus patient.
Topics: Aged; Aspirin; Blood Coagulation Factors; Factor VIIa; Humans; Lupus Coagulation Inhibitor; Male; Re | 2009 |
Impact of chronic antithrombotic therapy on hospital course of patients with acute myocardial infarction.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Bundle-Branch Block; Coumarins; Diabetes Mellitus; Femal | 2009 |
Cardiorenal syndromes--recommendations from clinical practice guidelines: the cardiologist's view.
Topics: Acute Disease; Acute Kidney Injury; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhib | 2010 |
Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Anemia; Angioplasty; Anticoagulants; Antihypertensive Ag | 2011 |
Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inh | 2002 |
Acute myocardial infarction and renal dysfunction: a high-risk combination.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2002 |
Summaries for patients. Kidney disease and heart attacks.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inh | 2002 |
Summaries for patients. The influence of kidney disease on outcomes of patients with heart attack.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2002 |
Staying alive after heart bypass.
Topics: Aspirin; Coronary Artery Bypass; Humans; Myocardial Infarction; Renal Insufficiency; Stroke; Surviva | 2002 |
Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Creatinine; Drug Monitoring; Eno | 2003 |
THE USE OF THE ARTIFICIAL KIDNEY IN THE COMMUNITY HOSPITAL.
Topics: Acute Kidney Injury; Aspirin; Geriatrics; Hospitals, Community; Kidney; Kidneys, Artificial; Poisoni | 1963 |
ACUTE RENAL FAILURE FOLLOWING ACETOPHENETIDIN INGESTION.
Topics: Acidosis; Acute Kidney Injury; Aspirin; Caffeine; Diabetes Mellitus; Diabetic Ketoacidosis; Diagnosi | 1964 |
ACUTE SALICYLATE POISONING IN ADULTS.
Topics: Acute Kidney Injury; Aspirin; Blood Chemical Analysis; Bronchopneumonia; Coma; Diagnosis, Differenti | 1964 |
NEPHROPATHY ASSOCIATED WITH THE USE OF ANALGESIC MEDICATIONS.
Topics: Acute Kidney Injury; Amobarbital; Analgesics; Analgesics, Non-Narcotic; Anti-Bacterial Agents; Antip | 1965 |
Beneficial effect of aspirin on renal function post-cardiopulmonary bypass.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiopulmonary Bypass; Coronary Artery Bypass; Creatinine; | 2003 |
[Interventional radiologic management for early post-transplant perfusion failure of renal allografts].
Topics: Aged; Angiography; Angiography, Digital Subtraction; Angioplasty, Balloon; Aspirin; Fibrinolytic Age | 2004 |
Use of beta-blockers and aspirin after myocardial infarction by patient renal function in the Department of Defense health care system.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Creatinine; Cross-Sectional Studies; Drug Utilization; F | 2006 |
Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Angi | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 2008 |
Safety of labor epidural anesthesia for women with severe hypertensive disease. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.
Topics: Adult; Anesthesia, Epidural; Aspirin; Cesarean Section; Chronic Disease; Double-Blind Method; Female | 1999 |
Analgesic use and renal function in men.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort St | 2001 |
Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction.
Topics: Abciximab; Aged; Angina Pectoris; Antibodies, Monoclonal; Aspirin; Biomarkers; Creatinine; Female; H | 2002 |